PRNewsWire
26 Jul 2026, 17:59 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The EMA's CHMP issued a positive opinion recommending the authorization of Ubeslo (Obicetrapib monotherapy) and Evlarco (Obicetrapib/Ezetimib combination). — A positive CHMP opinion is a primary regulatory catalyst that significantly increases the probability of EU market entry and future revenue.
+0.80NewAmsterdam Pharma is entitled to double-digit royalties and up to 833 million euros in milestone payments from Menarini Group for European commercialization. — This outlines a direct and substantial financial windfall for NewAmsterdam upon regulatory approval and commercial success.
+0.50Phase 3 data (BROADWAY, BROOKLYN, TANDEM) demonstrated LDL-C reductions of up to 40% for monotherapy and 50% for combination therapy compared to placebo. — Strong clinical efficacy data supports the commercial viability and competitive positioning of the drug against existing therapies.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The final decision on authorization from the European Commission is expected in the second half of 2026. — Provides a clear timeline for the next catalyst, though the outcome is largely expected to follow the CHMP's recommendation.
+0.10Which stocks this story touches
The company received a positive CHMP opinion recommending the approval of its drugs Ubeslo and Evlarco in Europe.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1h ago
